NCT00668304已完成4 期
Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial Eradication and Key Symptom Relief in the Treatment of Acute Bacterial Maxillary Sinusitis With Moxifloxacin 400 mg QD
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 192
- 主要终点
- Time to bacteriological eradication in those who are microbiologically valid for S. pneumoniae, M. catarrhalis, and H. influenzae
研究概览
简要总结
This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of acute sinusitis with signs and symptoms present for >7 days but < 28 days as defined by A), radiographic, and B) clinical criteria, as follows:a. The presence of 1 or more of the following on a radiographic paranasal sinus film (Waters' view) or limited CT scan:** evidence of air-fluid levels** opacification. The presence of at least one major and one minor symptom as defined in the list below:** Major Symptoms*** Purulent anterior or posterior nasal discharge*** Unilateral moderate or severe facial pain or malar tenderness** Minor Symptoms*** Cough or frequent throat clearing*** Frontal headache*** Halitosis*** Fever (oral > 38.0°C/100.4°F, tympanic > 38.5°C/101.2°F)*** Purulent secretions obtained via middle meatus secretion sampling using nasal endoscopic technique; the specimen sent for Gram stain, culture and susceptibility testing prior to initiation of antimicrobial therapy
排除标准
- •History of chronic sinusitis defined as greater than four weeks of continuous symptoms (patients with history of sinus surgery may be included; patients with recurrent sinusitis may be included)
- •Known bacteremia, meningitis or infection infiltrating the tissues neighboring the sinuses- Received systemic antibacterial therapy likely to be effective in sinusitis for more than 24 hours within 7 days of enrollment- A requirement for concomitant systemic antibacterial therapy with agents other than those specified in this protocol- Known immunodeficiency diseases including AIDS (CD4 <200)- On topical nasal or systemic corticosteroids, unless they have been on a stable dose for > 4 weeks prior to enrollment- History of allergy to quinolone antibiotics or related compounds- Pregnant or breast feeding- Of childbearing potential in whom pregnancy cannot be excluded by a negative pregnancy test and who are not using reliable barrier method of contraception
- •Received an investigational drug in the past 30 days- Unable to take oral medication- Known to have congenital or sporadic syndromes of QTc prolongation or receiving concomitant medication reported to increase the QTc interval (e.g. amiodarone, sotalol, disopyramide, quinidine, procainamide, terfenadine)
- •End stage liver cirrhosis (class Child-Pugh C)- Severe renal impairment requiring dialysis
- •Previous history of tendinopathy associated with quinolones- Any symptoms that suggest that the patient's current illness is allergic rhinitis (e.g., repetitive sneezing, itchy nose or eyes, provocation by an allergen) and not acute bacterial sinusitis
- •Diagnosis of rapidly fatal illness with a life expectance of less than 6 months- Previously enrolled in this clinical study- Uncorrected hypokalaemia
研究组 & 干预措施
Arm 1
Experimental
干预措施: Avelox (Moxifloxacin, BAY12-8039) (Drug)
结局指标
主要结局
Time to bacteriological eradication in those who are microbiologically valid for S. pneumoniae, M. catarrhalis, and H. influenzae
时间窗: Days 1, 2, 3 of treatment
次要结局
- Patient-reported symptom improvement using SNOT-16 questionnaire(Up to End of Treatment (Day 10-13))
- Adverse Events Collection(Up to End of Treatment (Day 10-13))
- Clinical Response(End of Treatment)
- Bacteriological Response(End of Treatment)
- Activity Impairment Assessment questionnaire(Up to End of Treatment (Day 10-13))
- Incidence of Premature Termination(Premature Termination)
研究者
相似试验
Unknown
2 期
Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)MalignancyAllogeneic Stem Cell TransplantationNCT00215007Charite University, Berlin, Germany
已完成
3 期
BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration PneumoniaPneumonia, AspirationLung AbscessNCT01045902Bayer139
已完成
3 期
A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired PneumoniaPneumoniaNCT00717561Bayer60
已完成
3 期
A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIsInfectious DiseasesNCT00828971Bayer16
Unknown
4 期
Efficacy of Three Antibiotic Protocols for Aggressive Periodontitis TreatmentAggressive PeriodontitisNCT02839421Facultad Nacional de Salud Publica36